Interventional Oncology

Preoperative Hepatic Augmentation: 2023 Update

Coordinator(s)

• 

  David Madoff, MD

  Professor of Radiology & Oncology; Vice Chair for Clinical Research; Section Chief, IR
  Yale School of Medicine

  Disclosure information not submitted.

This categorical course will highlight the most important aspects of preoperative hepatic augmentation by reviewing the following topics:
1. What's new in preoperative future liver remnant assessment?
2. Is PVE still standard of care or has its time come and gone?
3. Is there an ideal embolic agent for PVE and does it even matter?
4. ALPPS: is the risk worth the benefit?
5. Radiation lobectomy: real strategy or voodoo dosimetry?
6. Double venous embolization: what is the evidence to support its use?
7. Where are the opportunities for further advancements?

Presentations:

• 8:30 AM – 8:41 AM

  What's new in preoperative future liver remnant assessment?
  

  Speaker: Joshua Cornman-Homonoff, MD (he/him/his) – Yale University
• 8:41 AM – 8:52 AM

  Is PVE still standard of care or has its time come and gone?
  

  Speaker: Anne Covey, MD – Memorial Sloan-Kettering Cancer Center
• 8:52 AM – 9:03 AM

  Is there an ideal embolic agent for PVE and does it even matter?
  

  Speaker: Bruno Odisio, MD FSIR (he/him/his) – UT MD Anderson Cancer Center
• 9:03 AM – 9:14 AM

  Radiation lobectomy: real strategy or voodoo dosimetry?
  

  Speaker: Robert Lewandowski, MD, FSIR – Northwestern University
• 9:14 AM – 9:25 AM

  Double venous embolization: what is the evidence to support its adoption?
  

  Speaker: Daehee Kim, MD – Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University
• 9:25 AM – 9:36 AM

  Comparing the Techniques: Is there a Winner
  

  Speaker: Resmi A. Charalel, MD, MPH (she/her/hers) – Weill Cornell Medicine
• 9:36 AM – 9:47 AM

  What are the opportunities for further advancements in preoperative hepatic augmentation?
  

  Speaker: David Madoff, MD – Yale School of Medicine
• 9:47 AM – 10:00 AM

  Q & A